Electrolytes · Clinical Calculator · Dysnatremia

Sodium Trajectory & Correction-Limit Tracker Measured change · Rolling 24/48-hour windows

Enter each sodium with its collection time. The tracker reports the actual change over the actual elapsed time, the largest observed rise (or fall) inside every rolling 24- and 48-hour window, and whether a ceiling you selected from a named protocol was approached, reached, or exceeded. Earlier excursions stay on the record after relowering.

Published: References: 7 Read time:

← All calculators & tools  ·  Related guide →

Last ReviewedHuling Na-reviewKatapusang Na-reviewKarinan Na-review:
Instructions
  1. Choose the direction you are monitoring: a rising sodium during hyponatremia treatment, or a falling sodium during hypernatremia treatment.
  2. Record the onset. Unknown onset is handled as chronic.
  3. Select the named protocol whose ceilings you are following (or enter your institution’s values). The tracker never chooses ceilings for you.
  4. Enter each sodium with its collection date, time and time zone (not the result time). Add treatment events in the note column (no names or hospital numbers).

All computation runs in your browser. Nothing is stored or sent. Reloading the page clears every entry.

When to Use

Use it while sodium is being actively corrected — after hypertonic saline, isotonic fluid in hypovolemia, glucocorticoid replacement, stopping a thiazide, refeeding, tolvaptan or urea, and during free-water replacement in hypernatremia. Those are exactly the moments when a water diuresis can accelerate correction between blood draws. See the dysnatremia guide for the clinical pathway.

⚠️

What this tool does not do

It does not estimate the probability of osmotic demyelination syndrome (ODS), predict a future sodium, select a fluid or a desmopressin dose, or label any course “safe.” A short-interval rate is never presented as a 24-hour result. Sparse sampling can hide a peak, so incomplete windows are flagged rather than reassured.

Sodium Trajectory & Correction-Limit Tracker

Unknown is never treated as acute.
Product rule, configurable — not from a guideline.

Risk factors for osmotic demyelination (recorded separately; not a score)

Sodium observations

Collected (date, time)Sodium (mmol/L)MethodEvent / treatment note

⚕ Interval rate = (Naj − Nai) ÷ elapsed hours. Window maximum = the largest change between any two measured values collected within W hours of each other (W = 24 or 48), with its actual elapsed time. Equal to a ceiling = “at limit”; greater = “exceeded”; both compared before rounding. Formula version DYSNA-K 1.0.

Formulae & Evidence

Formulae

QuantityDefinition
Baseline-to-current changeLatest sodium − first sodium entered (the first entry is your episode reference)
Interval rate(Naj − Nai) ÷ hours between consecutive collections
Observed 24/48-hour maximummax over all pairs i < j with 0 < tj − ti ≤ W of (Naj − Nai) for a rise, or (Nai − Naj) for a fall
Coverage“Incomplete” when the entries span less than 24 hours; “sparse” when two consecutive samples are more than 6 hours apart

Protocol ceilings offered (quoted, not merged)

  • Conservative default for chronic or unknown onset: ≤8 mmol/L in any 24 h with a lower working target — an editorial safety choice for this site, not a claim that every guideline uses 8.
  • US/Irish expert recommendations, usual risk: limits of 10–12 mmol/L in 24 h and 18 mmol/L in 48 h, aiming below the limit; high ODS risk: aim 4–6 mmol/L/day and avoid more than 8 in any 24 h (Verbalis et al., 2013; Sterns et al., 2024).
  • European guideline (2014): ≤10 mmol/L in the first 24 h and ≤8 mmol/L in each subsequent 24 h (Spasovski et al., 2014).
  • Hypernatremia, chronic or unknown: conventional practice limits the fall to about 0.5 mmol/L/h and 10–12 mmol/L per day; adult evidence is observational and conflicting (Yun et al., 2023; You et al., 2026).

Key numbers

  • Osmotic demyelination: 0.23% overall in 11 cohorts (26,710 patients); 0.73% after rapid versus 0.10% after non-rapid correction (odds ratio 3.16, 95% confidence interval 1.54–6.49). Group incidences, not an individual risk (Suppadungsuk et al., 2025).
  • SALSA: overcorrection occurred in 17.2% with intermittent boluses and 24.2% with continuous infusion of 3% saline, with 6-hourly sampling (Baek et al., 2021).
Important: This tracker is an educational monitoring aid for clinicians. It does not diagnose, predict, or order treatment. Follow your institution’s approved protocol and obtain nephrology input when a ceiling is approached.
References 7 sources
  1. Spasovski, G., Vanholder, R., Allolio, B., Annane, D., Ball, S., Bichet, D., Decaux, G., Fenske, W., Hoorn, E. J., Ichai, C., Joannidis, M., Soupart, A., Zietse, R., Haller, M., van der Veer, S., Van Biesen, W., & Nagler, E. (2014). Clinical practice guideline on diagnosis and treatment of hyponatraemia. European Journal of Endocrinology, 170(3), G1–G47. https://doi.org/10.1530/EJE-13-1020
  2. Verbalis, J. G., Goldsmith, S. R., Greenberg, A., Korzelius, C., Schrier, R. W., Sterns, R. H., & Thompson, C. J. (2013). Diagnosis, evaluation, and treatment of hyponatremia: Expert panel recommendations. The American Journal of Medicine, 126(10 Suppl 1), S1–S42. https://doi.org/10.1016/j.amjmed.2013.07.006
  3. Sterns, R. H., Rondon-Berrios, H., Adrogué, H. J., Berl, T., Burst, V., Cohen, D. M., Christ-Crain, M., Cuesta, M., Decaux, G., Emmett, M., Garrahy, A., Gankam-Kengne, F., Hix, J. K., Hoorn, E. J., Kamel, K. S., Madias, N. E., Peri, A., Refardt, J., Rosner, M. H., . . . Verbalis, J. G. (2024). Treatment guidelines for hyponatremia: Stay the course. Clinical Journal of the American Society of Nephrology, 19(1), 129–135. https://doi.org/10.2215/CJN.0000000000000244
  4. Suppadungsuk, S., Krisanapan, P., Kazeminia, S., Nikravangolsefid, N., Singh, W., Prokop, L. J., Kashani, K. B., & Domecq Garces, J. P. (2025). Hyponatremia correction and osmotic demyelination syndrome risk: A systematic review and meta-analysis. Kidney Medicine, 7(3), 100953. https://doi.org/10.1016/j.xkme.2024.100953
  5. Baek, S. H., Jo, Y. H., Ahn, S., Medina-Liabres, K., Oh, Y. K., Lee, J. B., & Kim, S. (2021). Risk of overcorrection in rapid intermittent bolus vs slow continuous infusion therapies of hypertonic saline for patients with symptomatic hyponatremia: The SALSA randomized clinical trial. JAMA Internal Medicine, 181(1), 81–92. https://doi.org/10.1001/jamainternmed.2020.5519
  6. Yun, G., Baek, S. H., & Kim, S. (2023). Evaluation and management of hypernatremia in adults: Clinical perspectives. The Korean Journal of Internal Medicine, 38(3), 290–302. https://doi.org/10.3904/kjim.2022.346
  7. You, J., Shim, S.-R., Yun, G., Koh, E. S., Yu, M.-Y., Kim, H. J., Lee, J., Kim, S., & Baek, S. H. (2026). Association of serum sodium correction rate with clinical outcomes in adults with hypernatremia: A systematic review and meta-analysis. Kidney Research and Clinical Practice. Advance online publication. https://doi.org/10.23876/j.krcp.26.419
Dr. W Rivero, MD

W Rivero, MD, FPCP, DPSN

Specialist in Internal Medicine, Nephrology, and Clinical Nutrition. Practicing integrative and evidence-based nephrology across Quezon City, Pampanga, and Bulacan.

· Book an Appointment →

QR code — scan to save Dr. Rivero's contact info

Scan and save

All Calculators Related Guides